TITLE

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

AUTHOR(S)
Dannon, Pinhas N.; Iancu, Iulian; Cohen, Ami; Lowengrub, Katherine; Grunhaus, Leon; Kotler, Moshe
PUB. DATE
January 2004
SOURCE
BMC Psychiatry;2004, Vol. 4, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: This naturalistic open label follow-up study had three objectives: 1) To observe the course of illness in Panic Disorder patients receiving long-term versus intermediate-term paroxetine treatment 2) To compare the relapse rates and side-effect profile after long-term paroxetine treatment between patients with Panic Disorder and Panic Disorder with Agoraphobia. 3) To observe paroxetine's tolerability over a 24 month period. Methods: 143 patients with panic disorder (PD), with or without agoraphobia, successfully finished a short-term (ie 12 week) trial of paroxetine treatment. All patients then continued to receive paroxetine maintenance therapy for a total of 12 months. At the end of this period, 72 of the patients chose to discontinue paroxetine pharmacotherapy and agreed to be monitored throughout a one year discontinuation follow-up phase. The remaining 71 patients continued on paroxetine for an additional 12 months and then were monitored, as in the first group, for another year while medication-free. The primary limitation of our study is that the subgroups of patients receiving 12 versus 24 months of maintenance paroxetine therapy were selected according to individual patient preference and therefore were not assigned in a randomized manner. Results: Only 21 of 143 patients (14%) relapsed during the one year medication discontinuation follow-up phase. There were no significant differences in relapse rates between the patients who received intermediate-term (up to 12 months) paroxetine and those who chose the long-term course (24 month paroxetine treatment). 43 patients (30.1%) reported sexual dysfunction. The patients exhibited an average weight gain of 5.06 kg. All patients who eventually relapsed demonstrated significantly greater weight increase (7.3 kg) during the treatment phase. Conclusions: The extension of paroxetine maintenance treatment from 12 to 24 months did not seem to further decrease the risk of relapse after medication discontinuation. Twenty-four month paroxetine treatment is accompanied by sexual side effects and weight gain similar to those observed in twelve month treatment.
ACCESSION #
29323657

 

Related Articles

  • Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. Leinonen, Esa; Lepola, Ulla; Koponen, Hannu; Turtonen, Jukka; Wade, Allan; Lehto, Heikki // Journal of Psychiatry & Neuroscience;Jan2000, Vol. 25 Issue 1, p24 

    Examines the effects of long-term treatment with the selective serotonin reuptake inhibitor citalopram or clomipramine on subjective phobic symptoms in patients with panic disorders. Details of the study design; Description of subject patients; Measurement of the phobic symptoms; Citalopram's...

  • Marital Interactions in Predicting Treatment Outcome in Panic Disorder with Agoraphobia. El-Baalbaki, Ghassan; Bélanger, Claude; Perreault, Michel; Fredman, Steffany J.; Baucom, Donald H. // World Academy of Science, Engineering & Technology;Jun2010, Issue 42, p236 

    No abstract available.

  • Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data. Wade, Alan G; Fernández, José-Luis; François, Clément; Hansen, Karina; Danchenko, Natalya; Despiegel, Nicolas // PharmacoEconomics;2008, Vol. 26 Issue 11, p969 

    BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are approved for the treatment of major depressive disorder (MDD). The allosteric SSRI escitalopram has been shown to be at least as clinically effective as the SNRIs venlafaxine...

  • Dapoxetine: a guide to its use in premature ejaculation.  // Drugs & Therapy Perspectives;Feb2011, Vol. 27 Issue 2, p1 

    Dapoxetine, a selective serotonin reuptake inhibitor, is indicated for the treatment of premature ejaculation in men aged 18-64 years. In well designed clinical trials in men with premature ejaculation, treatment with dapoxetine significantly increased intravaginal ejaculation latency times...

  • CBT, SSRI or both are similarly effective for panic disorder 1-year post-treatment.  // Evidence Based Mental Health;Nov2010, Vol. 13 Issue 4, p125 

    The article discusses a study on the long-term effectiveness of cognitive behavioural therapy (CBT), pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI) or the combination of both for panic disorder. The study included adults with a primary diagnosis of Diagnostic and...

  • Selective Serotonin Reuptake Inhibitors for Treatment of Selective Mutism. Çöpür, Mazlum; Görker, Işık; Demir, Türkay // Balkan Medical Journal;Mar2012, Vol. 29 Issue 1, p99 

    Some authors suggest that selective mutism should be considered as a variant of social phobia or a disorder in the obsessive-compulsive spectrum. Recent studies indicate that pharmacological treatments may be effective in the treatment of selective mutism. In this article, four cases who were...

  • SSRIs provide modest benefit in selected patients with IBS.  // BMJ: British Medical Journal (International Edition);11/13/2004, Vol. 329 Issue 7475, p1112 

    Presents a question and answer column concerning the use of selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Synopsis of the use of the drugs and a randomised trial to see if the medications had value; Finding that a there was a small benefit to using...

  • Key differences between triptans relate to their pharmacokinetic profiles and available formulations.  // Drugs & Therapy Perspectives;Mar2011, Vol. 27 Issue 3, p15 

    Triptans are the treatment of choice in patients with migraine. A number of triptans are available, but they are all similarly very effective with few adverse events. The main points of differentiation between the agents relate to their pharmacokinetic profile and available formulations.

  • Adjunctive cognitive behavioural therapy improves response in children with OCD and partial response to serotonin reuptake inhibitors. Merlo, Lisa J. // Evidence Based Mental Health;Feb2012, Vol. 15 Issue 1, p22 

    The article highlights a clinical trial about the effects of adding cognitive behavioral therapy (CBT) to medication management in children with obsessive-compulsive disorder (OCD). Results of the trial revealed that adding CBT to medication management improved the response in OCD children as...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics